The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Antiretroviral-Drug Resistance among Patients Recently Infected with HIV
Open accessAbstract
BACKGROUND: Among persons in North America who are newly infected with the human immunodeficiency virus (HIV), the prevalence of transmitted resistance to antiretroviral drugs has been estimated at 1 to 11 percent. METHODS: We performed a retrospective analysis of susceptibility to antiretroviral drugs before treatment and drug-resistance mutations in HIV in plasma samples from 377 subjects with primary HIV infection who had not yet received treatment and who were identified between May 1995 and June 2000 in 10 North American cities. Responses to treatment could be evaluated in 202 subjects. RESULTS: Over the five-year period, the frequency of transmitted drug resistance increased significantly. The frequency of high-level resistance to one or more drugs (indicated by a value of more than 10 for the ratio of the 50 percent inhibitory concentration [IC50] for the subject's virus to the IC50 for a drug-sensitive reference virus) increased from 3.4 percent during the period from 1995 to 1998 to 12.4 percent during the period from 1999 to 2000 (P=0.002), and the frequency of multidrug resistance increased from 1.1 percent to 6.2 percent (P=0.01). The frequency of resistance mutations detected by sequence analysis increased from 8.0 percent to 22.7 percent (P<0.001), and the frequency of multidrug resistance detected by sequence analysis increased from 3.8 percent to 10.2 percent (P=0.05). Among subjects infected with drug-resistant virus, the time to viral suppression after the initiation of antiretroviral therapy was longer (P=0.05), and the time to virologic failure was shorter (P=0.05). CONCLUSIONS: The proportion of new HIV infections that involve drug-resistant virus is increasing in North America. Initial antiretroviral therapy is more likely to fail in patients who are infected with drug-resistant virus. Testing for resistance to drugs before therapy begins is now indicated even for recently infected patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
Finzi, D., Hermankova, M., Pierson, T., Carruth, L. M., Buck, C., Chaisson, R. E., Quinn, T. C., Chadwick, K., Margolick, J., Brookmeyer, R., et al. (1997) · Science · doi:10.1126/science.278.5341.1295 · Cited by 3,098
Self-citationRecovery of replication-competent HIV despite prolonged suppression of plasma viremia
Wong, J. K., Hezareh, M., Günthard, H. F., Havlir, D. V., Ignacio, C. C., Spina, C. A., & Richman, D. D. (1997) · Science · doi:10.1126/science.278.5341.1291 · Cited by 2,186
Self-citationAutran, B., Carcelain, G., Li, T. S., Blanc, C., Mathez, D., Tubiana, R., Katlama, C., Debré, P., & Leibowitch, J. (1997) · Science · doi:10.1126/science.277.5322.112 · Cited by 1,785
Carpenter, C. C. J., Cooper, D. A., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Hammer, S. M., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., et al. (2000) · JAMA · doi:10.1001/jama.283.3.381 · Cited by 1,012
Self-citationHirsch, M. S., Brun-Vézinet, F., D'Aquila, R. T., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Loveday, C., Mellors, J. W., Clotet, B., Conway, B., et al. (2000) · JAMA · doi:10.1001/jama.283.18.2417 · Cited by 766
Self-citationJanssen, R. S. (1998) · JAMA · doi:10.1001/jama.280.1.42 · Cited by 687
A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1
Petropoulos, C. J., Parkin, N. T., Limoli, K. L., Lie, Y., Wrin, T., Huang, W., Tian, H., Smith, D., Winslow, G. A., Capon, D. J., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.920-928.2000 · Cited by 646
Self-citationMurphy, E. L., Collier, A. C., Kalish, L. A., Assmann, S. F., Para, M. F., Flanigan, T. P., Kumar, P. N., Mintz, L., Wallach, F. R., Nemo, G. J., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-1-200107030-00005 · Cited by 573
Self-citationHirsch, M. S., Günthard, H. F., Schapiro, J. M., Brun‐Vézinet, F., Clotet, B., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Mellors, J. W., Pillay, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/589297 · Cited by 573
Self-citation
Cited by
Canonical WNT Signaling Promotes Osteogenesis by Directly Stimulating Runx2 Gene Expression
Gaur, T., Lengner, C. J., Hovhannisyan, H., Bhat, R. A., Bodine, P. V. N., Komm, B. S., Javed, A., van Wijnen, A. J., Stein, J. L., Stein, G. S., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500608200 · Cited by 1,170
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
Structural Violence and Clinical Medicine
Farmer, P. E., Nizeye, B., Stulac, S., & Keshavjee, S. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030449 · Cited by 1,131
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Can we safely target the WNT pathway?
Kahn, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4233 · Cited by 1,034
Clavel, F., & Hance, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejm2ra025195 · Cited by 800
Deeks, S. G., Overbaugh, J., Phillips, A., & Buchbinder, S. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.35 · Cited by 644
Hirsch, M. S., Günthard, H. F., Schapiro, J. M., Brun‐Vézinet, F., Clotet, B., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Mellors, J. W., Pillay, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/589297 · Cited by 573
Self-citationGulick, R. M., Ribaudo, H. J., Shikuma, C. M., Lustgarten, S., Squires, K. E., Meyer, W. A., Acosta, E. P., Schackman, B. R., Pilcher, C. D., Murphy, R. L., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031772 · Cited by 522
Hirsch, M. S., Brun‐Vezinet, F., Clotet, B., Conway, B., Kuritzkes, D. R., D’Aquila, R. T., Demeter, L. M., Hammer, S. M., Johnson, V. A., Loveday, C., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/375597 · Cited by 514
Self-citationNetworks and hubs for the transcriptional control of osteoblastogenesis
Lian, J. B., Stein, G. S., Javed, A., van Wijnen, A. J., Stein, J. L., Montecino, M., Hassan, M. Q., Gaur, T., Lengner, C. J., & Young, D. W. (2006) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-006-9001-5 · Cited by 468
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes
Matthews, T., Salgo, M., Greenberg, M., Chung, J., DeMasi, R., & Bolognesi, D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1331 · Cited by 465
Bunnell, R., Ekwaru, J. P., Solberg, P., Wamai, N., Bikaako-Kajura, W., Were, W., Coutinho, A., Liechty, C., Madraa, E., Rutherford, G., et al. (2006) · AIDS · doi:10.1097/01.aids.0000196566.40702.28 · Cited by 463
Crum, N. F., Riffenburgh, R. H., Wegner, S., Agan, B. K., Tasker, S. A., Spooner, K. M., Armstrong, A. W., Fraser, S., & Wallace, M. R. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000179459.31562.16 · Cited by 456
Antiretroviral therapy and management of HIV infection
Volberding, P. A., & Deeks, S. G. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60676-9 · Cited by 449
Li, F., Goila-Gaur, R., Salzwedel, K., Kilgore, N. R., Reddick, M., Matallana, C., Castillo, A., Zoumplis, D., Martin, D. E., Orenstein, J. M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2234683100 · Cited by 426
The prevalence of antiretroviral drug resistance in the United States
Richman, D. D., Morton, S. C., Wrin, T., Hellmann, N., Berry, S., Shapiro, M. F., & Bozzette, S. A. (2004) · AIDS · doi:10.1097/01.aids.0000131310.52526.c7 · Cited by 408
Self-citationMarkowitz, M., Nguyen, B.-Y., Gotuzzo, E., Mendo, F., Ratanasuwan, W., Kovacs, C., Prada, G., Morales-Ramirez, J. O., Crumpacker, C. S., Isaacs, R. D., et al. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318157131c · Cited by 408
Self-citationde Béthune, M.-P. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.09.008 · Cited by 401
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine
Cihlar, T., & Ray, A. S. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.09.014 · Cited by 375
Episodic Sexual Transmission of HIV Revealed by Molecular Phylodynamics
Lewis, F., Hughes, G. J., Rambaut, A., Pozniak, A., & Leigh Brown, A. J. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050050 · Cited by 374
Johnson, J. A., Li, J.-F., Wei, X., Lipscomb, J., Irlbeck, D., Craig, C., Smith, A., Bennett, D. E., Monsour, M., Sandstrom, P., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050158 · Cited by 371
Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?
Mehellou, Y., & De Clercq, E. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm900492g · Cited by 368
Koh, Y., Nakata, H., Maeda, K., Ogata, H., Bilcer, G., Devasamudram, T., Kincaid, J. F., Boross, P., Wang, Y.-F., Tie, Y., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3123-3129.2003 · Cited by 367
The role of nanotechnology in the treatment of viral infections
Singh, L., Kruger, H. G., Maguire, G. E. M., Govender, T., & Parboosing, R. (2017) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936117713593 · Cited by 360
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding
Lin, P.-F., Blair, W., Wang, T., Spicer, T., Guo, Q., Zhou, N., Gong, Y.-F., Wang, H.-G. H., Rose, R., Yamanaka, G., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1832214100 · Cited by 357
Hazuda, D. J., Anthony, N. J., Gomez, R. P., Jolly, S. M., Wai, J. S., Zhuang, L., Fisher, T. E., Embrey, M., Guare, J. P., Egbertson, M. S., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402357101 · Cited by 333
HIV-1 drug resistance and resistance testing
Clutter, D. S., Jordan, M. R., Bertagnolio, S., & Shafer, R. W. (2016) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2016.08.031 · Cited by 333
Strain, M. C., Little, S. J., Daar, E. S., Havlir, D. V., Günthard, H. F., Lam, R. Y., Daly, O. A., Nguyen, J., Ignacio, C. C., Spina, C. A., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/428777 · Cited by 331
Self-citationHIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
Shafer, R. W., Rhee, S.-Y., Pillay, D., Miller, V., Sandstrom, P., Schapiro, J. M., Kuritzkes, D. R., & Bennett, D. (2007) · AIDS · doi:10.1097/qad.0b013e328011e691 · Cited by 324
Human influences on evolution, and the ecological and societal consequences
Hendry, A. P., Gotanda, K. M., & Svensson, E. I. (2017) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2016.0028 · Cited by 298
Evolutionary principles and their practical application
Hendry, A. P., Kinnison, M. T., Heino, M., Day, T., Smith, T. B., Fitt, G., Bergstrom, C. T., Oakeshott, J., Jørgensen, P. S., Zalucki, M. P., et al. (2011) · Evolutionary Applications · doi:10.1111/j.1752-4571.2010.00165.x · Cited by 295
Bennett, D. E., Myatt, M., Bertagnolio, S., Sutherland, D., & Gilks, C. F. (2008) · Antiviral Therapy · doi:10.1177/135965350801302s04 · Cited by 291
Hamers, R. L., Wallis, C. L., Kityo, C., Siwale, M., Mandaliya, K., Conradie, F., Botes, M. E., Wellington, M., Osibogun, A., Sigaloff, K. C. E., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70149-9 · Cited by 287
Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques
Hazuda, D. J., Young, S. D., Guare, J. P., Anthony, N. J., Gomez, R. P., Wai, J. S., Vacca, J. P., Handt, L., Motzel, S. L., Klein, H. J., et al. (2004) · Science · doi:10.1126/science.1098632 · Cited by 285
Twenty years of therapy for HIV-1 infection
Pomerantz, R. J., & Horn, D. L. (2003) · Nature Medicine · doi:10.1038/nm0703-867 · Cited by 284
Kassahun, K., McIntosh, I., Cui, D., Hreniuk, D., Merschman, S., Lasseter, K., Azrolan, N., Iwamoto, M., Wagner, J. A., & Wenning, L. A. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016196 · Cited by 278
HIV Treatment Adherence, Drug Resistance, Virologic Failure: Evolving Concepts
B. Nachega, J., C. Marconi, V., U. van Zyl, G., M. Gardner, E., Preiser, W., Y. Hong, S., J. Mills, E., & Gross, R. (2011) · Infectious Disorders - Drug Targets · doi:10.2174/187152611795589663 · Cited by 271
High levels of adherence do not prevent accumulation of HIV drug resistance mutations
Bangsberg, D. R., Charlebois, E. D., Grant, R. M., Holodniy, M., Deeks, S. G., Perry, S., Conroy, K. N., Clark, R., Guzman, D., Zolopa, A., et al. (2003) · AIDS · doi:10.1097/00002030-200309050-00011 · Cited by 256
Metadata
- Authors
- Little, S. J., Holte, S., Routy, J.-P., Daar, E. S., Markowitz, M., Collier, A. C., Koup, R. A., Mellors, J. W., Connick, E., Conway, B., Kilby, M., Wang, L., Whitcomb, J. M., Hellmann, N. S., & Richman, D. D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08-08
- Volume
- 347
- Issue
- 6
- Pages
- 385-394
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2086783015
- Cited by
- 1,140
- References
- 23
- FWCI
- 65.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.